KIR3DL1 and neoplasm: Studies have shown that Vγ9Vδ2 TCR derived from different T cell clones, elicits different anti-tumor responses which were not correlated with the expression of NKG2D, CD158a, NKAT-2, or NKB-1 [60,61].